Table 1

Baseline characteristics (mean (SD)) of patients who entered the trial, randomised to receive omega-3 PUFA (Omacor) or placebo

Omega-3 PUFA concentrate Placebo
Patients (n)3029
Men/women (n)23/720/9
Diabetes mellitus (n)87
Simvastatin 40 mg/daily (n)1010
Simvastatin 20 mg/daily (n)2017
Simvastatin 10 mg/daily (n)02
Age (years)55.2 (7.0)54.8 (10.2)
Body mass index (kg/m2)28.8 (2.8)28.4 (4.2)
Fasting glucose (all patients) (mmol/l)6.7 (2.5)6.7 (2.7)
Fasting glucose (diabetic patients) (mmol/l)9.8 (2.6)10.8 (2.4)
HbA1c (all patients) (%)5.9 (1.4)5.4 (1.5)
HbA1c (diabetic patients) (%)6.7 (1.9)7.6 (1.3)
Plasma fibrinogen (g/l)3.5 (1.2)3.4 (1.4)
Serum phospholipid eicosapentaenoic acid (mg/l)21.6 (14.9)21.0 (12.7)
Serum phospholipid docosapentaenoic acid (mg/l)72.9 (24.5)75.4 (25.6)